RxDoctor Payments Data

Darren Dohman, OD

Optometrist · Aberdeen, SDNPI 1265524078

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson Vision Care, Inc. accounts for 94.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $11,674 and has fallen 97.7% since, to $273 in 2025. Among optometrist clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,801in general payments, 2019–2025

Across 75 payments — averaging $290.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$21K
  • Alcon$578
  • Bausch & Lomb Americas Inc.$421
  • Plexus Optix, Inc.$142
  • AbbVie$109
  • Tearlab Corp$25
  • plus $21 from 1 others

What the payments were for

  • Consulting fees$8,50039%
  • Speaking & faculty fees$11,40052%
  • Food & beverage$1,9019%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,801 in reported general payments places this provider in the 95th percentile of 206 optometrist providers in South Dakota.

See all optometrist providers in South Dakota

Medicare billing

Part B allowed, 2024
$91,898
Medicare patients
571
Services billed
1,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost24$15,721
Latanoprost233$3,758
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat58$1,737
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$1,725
Timolol Maleate65$1,410
Dorzolamide Hcl23$832
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$527
Brimonidine Tartrate27$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$109$15,72124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 optometrist providers in South Dakota.

Other optometrist in Aberdeen

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →